Hasan Jilaihawi

Hasan Jilaihawi

Auto-generated profile, based on publicly available information

Hasan Jilaihawi

Cedars-Sinai Medical Center, The Smidt Heart Institute, Los Angeles, CA (H.J.).

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2016 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
YAYigal Abramowitz
Yigal Abramowitz
TCTarun Chakravarty
Tarun Chakravarty
HJHasan Jilaihawi
Hasan Jilaihawi
JCJustin Cox
Justin Cox
RSRahul P. Sharma
Rahul P. Sharma
RMRaj R. Makkar
Raj R. Makkar

6 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SPShubhadarshini G Pawar
Shubhadarshini G Pawar
VPVivek Patel
Vivek Patel
TNTakashi Nagasaka
Takashi Nagasaka
PMPrateek Madaan
Prateek Madaan
AJAmir Ghaffari Jolfayi
Amir Ghaffari Jolfayi
AGAakriti Gupta
Aakriti Gupta
Background: Self‐expanding valves (SEVs) have demonstrated superior hemodynamic performance and comparable clinical outcomes to balloon‐expandable valves (BEVs) at 1 year in patients with a small aortic annulus. However, long‐term data are limited. This study aimed to evaluate 5‐year echocardiographic and clinical outcomes of SEVs versus BEVs in patients with small aortic annulus underwent transcatheter aortic valve replacement. Methods: We analyzed RESOLVE registry patients who underwent transcatheter aortic valve replacement at Cedars‐Sinai between 2015 and 2020. Patients with a small aortic annulus (<430 mm 2 by computed tomography) were included and followed for up to 5 years. The primary outcome was a composite of all‐cause mortality, stroke, or heart failure hospitalization. Secondary outcomes included myocardial infarction, pacemaker implantation, aortic valve reintervention, and structural bioprosthetic valve dysfunction. Results: Among 1392 transcatheter aortic valve replacement recipients, 423 (78 SEVs, 345 BEVs) met the small annulus criteria. SEVs were associated with lower transvalvular gradients and larger indexed effective orifice area at discharge and 1 year ( P <0.001). Moderate‐to‐severe paravalvular leak was more frequent with SEVs at 30 days (7.7% versus 1.5%, P <0.001), as was permanent pacemaker implantation (17.9% versus 6.1%, P <0.001). At 5 years, the primary outcome did not differ significantly (hazard ratio, 1.21; 95% CI, 0.81–1.82; P <0.33). All‐cause mortality, stroke, heart failure hospitalization, structural bioprosthetic valve dysfunction, and reintervention rates were similar between groups. Conclusion: Although SEVs provide better hemodynamic performance in patients with severe aortic stenosis and small annuli, this advantage did not translate into improved survival or reduced cardiovascular events at 5 years.

1 April 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
JAJung-Min Ahn
Jung-Min Ahn
SKSant Kumar
Sant Kumar
EKEuihong Ko
Euihong Ko
GMGossadi Mohammed
Gossadi Mohammed
KHKentaro Hayashida
Kentaro Hayashida
SPSeung-Jung Park
Seung-Jung Park
Surgical aortic valve (AV) replacement has been the standard treatment for patients with severe symptomatic degenerative AV stenosis (AS). In recent years, transcatheter AV replacement has emerged as an established alternative in selected patient populations, supported by robust evidence in tricuspid AS. However, there has been limited evaluation of transcatheter AV replacement in bicuspid AV AS. Recently, several observational studies have demonstrated the feasibility and safety of transcatheter AV replacement in bicuspid AV AS, and the use of newer-generation devices has shown encouraging outcomes. However, the incidence of procedural complications such as paravalvular regurgitation, permanent pacemaker implantation, and aortic root injury was more frequent in patients with bicuspid AV AS compared with tricuspid AS. We review the clinical evidence of transcatheter AV replacement for bicuspid AV AS and suggest the appropriate criteria for patient and device selection, implantation techniques, and further management.

12 November 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
JRJustyna Rzucidlo
Justyna Rzucidlo
VJVita Jaspan
Vita Jaspan
DPDarien Paone
Darien Paone
HJHasan Jilaihawi
Hasan Jilaihawi
YXYuhe Xia
Yuhe Xia
MWMathew Williams
Mathew Williams

1 February 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
RMRaj R. Makkar
Raj R. Makkar
RWRon Waksman
Ron Waksman
MGMark Groh
Mark Groh
MRMark J. Russo
Mark J. Russo
JHJames Hermiller
James Hermiller
GFGregory P. Fontana
Gregory P. Fontana

1 May 2021 in JACC
Verified
Journal Article
Closed access
SPSonja Paschke
Sonja Paschke
MQMichael Querijero
Michael Querijero
YHYuxin He
Yuxin He
HJHasan Jilaihawi
Hasan Jilaihawi
CSCezar Staniloae
Cezar Staniloae
MWMathew Williams
Mathew Williams